Pharmaceutical UK-based GW Pharmaceuticals, which focuses on its proprietary cannabinoid product platform, today announced that the US Food and Drug Administration has granted Fast Track designation to Sativex, composed primarily of two cannabinoids, for the treatment of pain in patients with advanced cancer, who experience inadequate analgesia during optimized chronic opioid therapy. 28 April 2014